PMID- 31144151
OWN - NLM
STAT- MEDLINE
DCOM- 20191220
LR  - 20211027
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 177
IP  - 1
DP  - 2019 Aug
TI  - Pathologic complete response rate according to HER2 detection methods in 
      HER2-positive breast cancer treated with neoadjuvant systemic therapy.
PG  - 61-66
LID - 10.1007/s10549-019-05295-9 [doi]
AB  - PURPOSE: Human epidermal growth factor receptor 2 (HER2)-positive breast cancers 
      are known to have significant clinical and pathological response to neoadjuvant 
      systemic therapy (NST). The aim of this study was to identify factors associated 
      with pathological complete response (pCR), defined as no residual invasive 
      carcinoma in the breast and axillary lymph nodes (ypT0/is ypN0), among patients 
      with HER2-positive breast cancer and to compare pCR rates between breast cancers 
      with HER2 protein overexpression by immunohistochemistry (IHC) versus HER2 gene 
      amplification by fluorescence in situ hybridization (FISH) in the absence of 
      protein overexpression by IHC. METHODS: We conducted a retrospective review of 
      HER2-positive breast cancer patients treated with NST and surgery at Memorial 
      Sloan Kettering Cancer Center between January 2013 and May 2018. Estrogen 
      receptor (ER), progesterone receptor (PR), and HER2 status were assessed 
      according to the 2018 ASCO/CAP guidelines. RESULTS: During the study period, 560 
      patients were identified. Of 531 patients with IHC results available, 455 
      patients had HER2 IHC 3+, and 76 had IHC < 3+ but HER2 amplification detected by 
      FISH. The overall pCR rate was 59% (330/560). The pCR rate among patients with 
      HER2 protein overexpression (IHC 3+) was 67%, compared to 17% among patients with 
      HER2 amplification by FISH (IHC < 3+). On univariate and multivariate analyses, 
      HER2 protein overexpression by IHC (IHC 3+) was a significant predictor of pCR, 
      along with grade 3 histology, PR-negative status, and dual anti-HER2 therapy. 
      CONCLUSION: Although both HER2 IHC and FISH are standard HER2 testing methods in 
      breast cancer, achievement of pCR is associated with HER2 IHC expression level, 
      among other factors.
FAU - Krystel-Whittemore, Melissa
AU  - Krystel-Whittemore M
AD  - Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
FAU - Xu, Jin
AU  - Xu J
AD  - Department of Pathology, Memorial Sloan Kettering Cancer, 1275 York Avenue, New 
      York, NY, 10065, USA.
FAU - Brogi, Edi
AU  - Brogi E
AD  - Department of Pathology, Memorial Sloan Kettering Cancer, 1275 York Avenue, New 
      York, NY, 10065, USA.
FAU - Ventura, Katia
AU  - Ventura K
AD  - Department of Pathology, Memorial Sloan Kettering Cancer, 1275 York Avenue, New 
      York, NY, 10065, USA.
FAU - Patil, Sujata
AU  - Patil S
AD  - Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer, 
      New York, NY, USA.
FAU - Ross, Dara S
AU  - Ross DS
AD  - Department of Pathology, Memorial Sloan Kettering Cancer, 1275 York Avenue, New 
      York, NY, 10065, USA.
FAU - Dang, Chau
AU  - Dang C
AD  - Department of Medicine, Memorial Sloan Kettering Cancer, New York, NY, USA.
FAU - Robson, Mark
AU  - Robson M
AD  - Department of Medicine, Memorial Sloan Kettering Cancer, New York, NY, USA.
FAU - Norton, Larry
AU  - Norton L
AD  - Department of Medicine, Memorial Sloan Kettering Cancer, New York, NY, USA.
FAU - Morrow, Monica
AU  - Morrow M
AD  - Department of Surgery, Memorial Sloan Kettering Cancer, New York, NY, USA.
FAU - Wen, Hannah Y
AU  - Wen HY
AUID- ORCID: 0000-0001-6794-5234
AD  - Department of Pathology, Memorial Sloan Kettering Cancer, 1275 York Avenue, New 
      York, NY, 10065, USA. weny@mskcc.org.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P30CA008748/National Cancer Institute/
PT  - Journal Article
DEP - 20190529
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - *Biomarkers, Tumor
MH  - Biopsy, Large-Core Needle
MH  - Breast Neoplasms/*genetics/mortality/pathology/*therapy
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Receptor, ErbB-2/*genetics/metabolism
MH  - Receptors, Estrogen/genetics/metabolism
MH  - Receptors, Progesterone/genetics/metabolism
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC6640097
MID - NIHMS1530466
OTO - NOTNLM
OT  - HER2 assessment
OT  - HER2-positive breast cancer
OT  - Human epidermal growth factor receptor 2
OT  - Neoadjuvant systemic therapy
OT  - Pathologic complete response
COIS- Conflict of Interest: The authors have no conflict of interest to disclose.
EDAT- 2019/05/31 06:00
MHDA- 2019/12/21 06:00
PMCR- 2020/08/01
CRDT- 2019/05/31 06:00
PHST- 2019/04/06 00:00 [received]
PHST- 2019/05/23 00:00 [accepted]
PHST- 2019/05/31 06:00 [pubmed]
PHST- 2019/12/21 06:00 [medline]
PHST- 2019/05/31 06:00 [entrez]
PHST- 2020/08/01 00:00 [pmc-release]
AID - 10.1007/s10549-019-05295-9 [pii]
AID - 10.1007/s10549-019-05295-9 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2019 Aug;177(1):61-66. doi: 10.1007/s10549-019-05295-9. 
      Epub 2019 May 29.